Streetbeat News

Price Targets

AMLX

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 10:10 am

NOW

Needham analyst Jack Andrews has reiterated a 'Buy' rating on ServiceNow (NYSE:NOW) and maintained a price target of $660.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 10:09 am

TNET

Needham analyst Kyle Peterson has maintained a 'Buy' rating on Trinet Group (NYSE:TNET) and raised the price target from $115 to $120.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 10:01 am

FIHL

JP Morgan analyst Pablo Singzon has initiated coverage on Fidelis Insurance Hldgs (NYSE:FIHL) with an Overweight rating and a price target of $16.5.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 10:00 am

GPCR

Piper Sandler analyst Yasmeen Rahimi has initiated coverage on Structure Therapeutics (NASDAQ:GPCR) with an Overweight rating and a price target of $58.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 9:58 am

TPIC

Roth MKM analyst Philip Shen has downgraded TPI Composites (NASDAQ:TPIC) from Buy to Neutral and lowered the price target from $15 to $10.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 9:56 am

COTY

Jefferies analyst Stephanie Wissink has downgraded Coty (NYSE:COTY) from Buy to Hold and lowered the price target from $16 to $14.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 9:55 am

EL

Jefferies analyst Ashley Helgans has downgraded Estee Lauder Cos (NYSE:EL) from Buy to Hold and lowered the price target from $270 to $190.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 9:55 am

KOD

UBS analyst Eliana Merle has downgraded Kodiak Sciences (NASDAQ:KOD) from Buy to Neutral and lowered the price target from $15 to $4.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 9:53 am

VRE

Evercore ISI Group analyst Steve Sakwa has upgraded Veris Residential (NYSE:VRE) from In-Line to Outperform and raised the price target from $18 to $19.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 9:48 am